| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms |
| 27 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Seasoned oncology executive brings extensive clinical development expertise and a track record of advancing innovative cancer therapies |
| 22 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 22, 2026, Cardiff Oncology, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). A total of 48,084,246 shares of common stock, constituting a quorum, were represented in person or by valid pro... |
| 14 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC |
| 16 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of July 14, 2026, between Cardiff Oncology, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its ... |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Cardiff Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 41,614,848 shares of common stock, constituting a quorum, were represented in person or by valid proxies ... |
| 03 Jun 2026 |
8-K: Regulation FD Disclosure
June 3, 2026 Interim Results from the Randomized, Controlled Phase 2 CRDF-004 Trial Onvansertib + SoC Chemo/Bevacizumab in First-Line RAS-Mutated mCRC |
| 29 May 2026 |
8-K: Entry into a Material Definitive Agreement
As previously disclosed, on May 19, 2026, Cardiff Oncology, Inc. (the “Company”) filed a lawsuit against Nerviano Medical Sciences S.r.l. (“NMS”) disputing NMS’s allegation that the Company materially breached the License Agreement dated... |
| 19 May 2026 |
8-K: Other Events
On May 19, 2026, Cardiff Oncology, Inc. (the “Company”) filed a lawsuit against Nerviano Medical Sciences S.r.L (“NMS”) disputing NMS’s allegation that the Company materially breached its license agreement (Agreement) for onvansertib. Th... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update |
| 09 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive Officer |
| 02 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation
Previously on January 26, 2026, Cardiff Oncology, Inc. (the “Company”) disclosed that Dr. Mark Erlander, CEO and James Levine, CFO had stepped down from their respective roles at the Company as part of a strategic review. On March 27, 20... |
| 25 Feb 2026 |
8-K: Regulation FD Disclosure
Forward-looking statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate... |
| 24 Feb 2026 |
8-K: Completion of Acquisition or Disposition of Assets
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: |
| 27 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – |
| 29 Jul 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) – |
| 26 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 26, 2025, Cardiff Oncology, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 38,649,891 shares of common stock, constituting a quorum, were represented in person or by valid proxies ... |
| 17 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
This Employment Agreement (the “Agreement”) is made and entered into effective as of June 16, 2025 (the “Effective Date”), by and between Roger Sidhu (the “Executive”) and Cardiff Oncology, Inc., a Delaware corporation (the “Company”). |
Loading...